Taletrectinib Shows Promise in ROS1-Positive NSCLC, Including TKI-Pretreated Patients
核心洞察
Taletrectinib demonstrated an 85.2% confirmed overall response rate (cORR) in ROS1 (搜索) TKI-naive patients with locally advanced or metastatic NSCLC (搜索) in the TRUST-II trial.
In patients previously treated with ROS1 (搜索) TKIs, taletrectinib achieved a 61.7% cORR, indicating its potential in overcoming resistance.
The TRUST-II trial also showed notable intracranial response rates of 66.7% and 56.3% in TKI-naive and TKI-pretreated patients, respectively.
Taletrectinib (AB-106) has shown promising efficacy in patients with ROS1 (搜索)-positive non-small cell lung cancer (NSCLC (搜索)), according to data from the phase 2 TRUST-II trial (NCT04919811). The global, single-arm, open-label, multicenter study evaluated taletrectinib in patients with locally advanced or metastatic ROS1-positive NSCLC, regardless of prior TKI exposure.
High Response Rates Observed
At the 2024 IASLC World Conference on Lung Cancer, investigators presented data showing a confirmed overall response rate (cORR) of 85.2% (95% CI, 72.88%-93.38%) in patients without prior exposure to a ROS1 (搜索) TKI (n = 54). For patients previously treated with a ROS1 TKI (n = 47), the cORR with taletrectinib was 61.7% (95% CI, 46.38%-75.49%). The median follow-up was 15.8 months (range, 3.6-29.8) for TKI-naive patients and 15.7 months (range, 3.9-29.8) for TKI-pretreated patients.
Intracranial Activity
The TRUST-II study also demonstrated notable intracranial response rates. Among TKI-naive patients (n = 9), the intracranial response rate was 66.7% (95% CI, 29.93%-92.51%). In TKI-pretreated patients (n = 16), the intracranial response rate was 56.3% (95% CI, 29.88%-80.25%).
Tolerability
The treatment was generally well tolerated, although dose reductions were required in 37.1% of patients, with 16.4% of these reductions due to elevated liver enzymes. Jyoti Patel, MD, from Northwestern University, emphasized that taletrectinib has shown efficacy in patients with ROS1 (搜索) translocations, which are notoriously difficult to treat.